VRTX

Vertex Pharmaceuticals
D

VRTX

375.66
USD
-9.99
(-2.59%)
مغلق
حجم التداول
0
الربح لكل سهم
18
العائد الربحي
-
P/E
27
حجم السوق
96,315,711,955
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 11 شهر
buy
2024-08-22 05:31
VRTX Chart
المزيد
أصول ذات صلة
ABBV
ABBV
2.670
(1.36%)
198.950 USD
AMGN
AMGN
-0.02
(-0.01%)
284.68 USD
BIIB
BIIB
-1.730
(-1.34%)
127.690 USD
BMRN
BMRN
-1.190
(-1.96%)
59.460 USD
GILD
GILD
0.050
(0.05%)
110.350 USD
INCY
INCY
0.575
(0.74%)
78.230 USD
LLY
LLY
-105.58
(-14.15%)
640.51 USD
REGN
REGN
5.11
(0.92%)
560.19 USD
المزيد
الأخبار المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.